A Prognostic Biomarker for Gastric Cancer With Lymph Node Metastases

Abstract

Gastric cancer is one of the leading causes of tumor-related deaths in China. The tumor, node, metastasis (TNM) classification system is useful for predicting clinical prognosis of patients with gastric cancer. However, determining the presence of lymph node involvement in the early stages of gastric cancer is difficult without biopsy. Therefore, it is necessary to identify novel serum biomarkers for TNM cancer staging and prognostic follow-up. In this study, we have reported fibrinopeptide-A (FPA) with alanine truncation at the N-terminal as a novel biomarker to differentiate gastric cancer with and without lymph node metastases. We analyzed 369 individual serum samples including gastric cancer patients without lymph node metastases (n 5 33), gastric cancer patients with lymph node metastases (n 5 157; confirmed by pathology), and age-and sex-matched healthy individuals (n 5 179). The data showed that 85.4% of patients with lymph node metastases were positive for FPA with alanine truncation at the N-terminal (degAla-FPA, 1,465.63 Da), as determined by tandem mass spectrometry (MS). Using degAla-FPA as the biomarker, the sensitivity was 85.4% for gastric cancer patients with lymph node metastases, and the specificity was 100% for gastric cancer patients without lymph node metastases. The high sensitivity and specificity achieved with serum degAla-FPA levels indicated that MS technology could facilitate the discovery of a novel and quantitative prognostic biomarker for gastric cancer with lymph node involvement. Anat Rec, 296:590-594,

FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway

“…29, 30 Zhang et al have investigated novel N-glycan changes involved in drug resistance between leukemia cell line K562 and ADR-resistant K562/ADR using MALDI-TOF/MS. 31 Moreover, differential N-glycan compositions of human breast cancer cell line MCF-7 and its ADR-resistant counterpart MCF-7/ADR were identified using MS (MALDI-TOF /MS). 32 In this regard, our present work was aimed to MS investigation of N-glycans in parental and drug-resistant human HCC cell lines.…”

Coagulation and fibrinolysis in gastric cancer

“…The GC patients globally showed higher levels of FpA compared with healthy controls, so FpA was proposed as a potential marker for GC detection (Table ). Serum peptidome analyses by either matrix‐assisted laser‐desorption ionization or surface‐enhanced laser‐desorption ionization time‐of‐flight mass spectrometry revealed FpA peptide as a m/z peak at around 1469 Da particularly upregulated in metastatic GC or in GC with lymph node metastasis, as well as in patients at high risk for GC . Previous laboratory assays showed that FpA levels increased with the extent of primary tumor in postoperative patients with malignant disease since its early stages …”

“…Serum peptidome analyses by either matrix-assisted laser-desorption ionization or surface-enhanced laser-desorption ionization time-of-flight mass spectrometry revealed FpA peptide as a m/z peak at around 1469 Da particularly upregulated in metastatic GC or in GC with lymph node metastasis, as well as in patients at high risk for GC. [120][121][122][123] Previous laboratory assays showed that FpA levels increased with the extent of primary tumor in postoperative patients with malignant disease since its early stages. [124][125][126][127] Fibrinolysis: DD as an indicator of thrombosis, cancer progression, and response to therapy As a compensation mechanism for fibrin clot formation, fibrinolysis is activated, which consists of fibrin degradation by the sequential action of three enzymes: thrombin, factor XIIIa, and plasmin.…”

Case of Thrombosis of Rare Localization in a Cancer Patient with Combined form of Thrombophilia

“…Fibrin fibers are always present in any tumor tissue, which is particularly characteristic of the active zone of proliferation of malignant cells. A powerful fibrin barrier is formed due to distortion of the processes of permanent stimulation of fibrinogenesis and concomitant fibrinolysis in the tumor zone [5,6]. From the side of tumor cells, the initiating effect on the components of the hemostasis system and the process of fibrin formation is mediated by macrophages present in the tumor zone, whose reaction to malignant cells is expressed by increased production of proinflammatory cytokines, such as TNFα, IL-1, IL-6, IL-8 and other active molecules [7,8].…”